Inovio Pharma (AMEX:INO) has gained 1.8% or two cents a share to settle at $1.13 with a total traded volume of 191,000 shares. For the past 52 weeks the stock has been trading between $.76 and $1.56 a share with an average volume of 422,000 shares. Company has a market cap of $117 million and trades with an average beta of 2.69.

Inovio Pharmaceuticals, Inc., formerly Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of vaccines, called deoxyribonucleic acid (DNA) vaccines, focused on cancers and infectious diseases. The Company's SynCon technology enables the design of universal DNA-based vaccines capable of providing cross-protection against new, unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines.

Maxygen, Inc. (NASDAQ:MAXY) has gained 24% to settle at $5.10 with a total traded volume of 1.07 million shares. For the past 52 weeks the stock has been trading between $3.75 and $7.19 with an average volume of 101,000 shares. Company has a market cap of $154 million and trades with an average beta of 0.73.

Maxygen, Inc. (Maxygen) is a biopharmaceutical company focused on developing improved versions of protein drugs through internal development and external collaborations and other arrangements. The Company uses its MolecularBreeding directed technology platform, along with ancillary technologies, and protein modification to pursue the creation of biosuperior proteins. The Company operates all of its research and development operations through Perseid Therapeutics LLC (Perseid), a majority owned subsidiary.

The Greenbrier Companies (NYSE:GBX) has lost 0.84% to settle at $27.28 with a total traded volume of 174,000 shares. For the past 52 weeks it has traded between $9.10 and $28.60 with an average volume of 329,000 shares. Company has a market cap of $679 million and trades with an average beta of 2.97.

The Greenbrier Companies, Inc. (Greenbrier) is a designer, manufacturer and marketer of railroad freight car equipment in North America and Europe; a manufacturer and marketer of ocean-going marine barges in North America, and provider of wheel services, railcar refurbishment and parts, leasing and other services to the railroad and related transportation industries in North America. The Company operates an integrated business model in North America that combines wheel services, repair and refurbishment, component parts reconditioning, freight car manufacturing, leasing and fleet management services. It operates in three business segments: Manufacturing, Wheel Services, Refurbishment and Parts, and Leasing and Services.

TransAtlantic Petroleum (AMEX:TAT) has gained 4.39% to settle at $3.09 with a total traded volume of 1.83 million shares. For the past 52 weeks the stock has been trading between $2.68 and $4.10 with an average volume of 1.29 million shares. Company has a market cap of $1.04 billion and trades with an average beta of 1.3.

TransAtlantic Petroleum Ltd., formerly TransAtlantic Petroleum Corp., is an international oil and gas company engaged in the acquisition, development, exploration, and production of crude oil and natural gas. The Company holds interests in developed and undeveloped oil and gas properties in Turkey, Morocco, Romania, and California. It owns its own drilling rigs and oilfield service equipment, which it uses to develop its properties in Turkey and Morocco. In addition, it provides oilfield services and contract drilling services to third parties in Turkey.

Harbin Electric (NASDAQ:HRBN) has gained 1.02% to settle at $16.85 with an total traded volume of 530,000 shares. For the past 52 weeks the stock has been trading between $14.95 and $25.05 with an average volume of 216,000 shares. Company has a market cap of $527 million and trades with an average beta of 2.25.

Harbin Electric, Inc. (Harbin Electric) is a holding company. It designs, develops, manufactures, supplies and services a range of electric motors, including linear motors, specialty micro-motors and industrial rotary motors. It sells its products in China, but also to certain international markets. The Company operates four manufacturing facilities in China: Harbin Tech Full Electric Co., Ltd. (Harbin Tech Full), Shanghai Tech Full Electric Co., Ltd. (Shanghai Tech Full), Weihai Tech Full Simo Motor Co., Ltd. (Weihai Tech Full) and Xi'an Tech Full Simo Motor Co., Ltd. (Xi'an Tech Full Simo).

BullsEyeMicrocaps.com is not a registered investment advisers or broker/dealer. BullsEyeMicrocaps.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: BullsEyeMicrocaps.com has not been compensated for any stocks listed in this stock news report.

Inovio Pharma (AMEX:INO) has recently announced the publication of the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon vaccine for prostate cancer targeting two antigens. The resultant data showed the induction of strong PSMA-specific cellular immune responses and also significant antigen specific seroconversion, illustrating that both humoral and cellular immune responses can be generated by this approach.

Stock recently rallied by 1.79% to settle at $1.14 with an increased volume of 344,104. Keep an eye on this one as the increase in volume might push the stock for another breakout.

The development of this new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and often do not confer long-term cure.

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon(TM) DNA vaccine for prostate cancer targeting two antigens.

NovaBay Pharma (AMEX:NBY) has recently provided a synopsis of its accomplishment as well as the progress from 2010 and its outlook into 2011. NovaBay is in the process of developing commercial opportunities for its Aganocide portfolio of anti-infectives in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections.

Each of these market segments contain indications that are poorly served or have no approved FDA treatments available, with billion-dollar revenue potential. Company's strategy is to address these market opportunities either through partnerships and collaborations or by building an internal organization to strategically market its own products when appropriate from a commercial standpoint.

Shares have gained 5.64% to settle at $0.11 with a moderate volume of 53,654 shares traded by the opening bell.

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.

Plug Power (NASDAQ:PLUG) announced today that the NASDAQ Listing Qualifications Panel has granted the Company's request for continued listing on The NASDAQ Capital Market pursuant to an extension of time to comply with the minimum $1.00 bid price requirement. In accordance with the Panel's decision, before June 6, 2011, the Company must evidence compliance with the bid price requirement for a minimum of ten consecutive business days.

Shares lost 2.97% to settle at $0.65 with an increased volume of 1,675,158 shares traded so far.

Plug Power Inc. is a development-stage company engaged in the design, development and manufacture of fuel cell systems for industrial off-road (forklift or material handling) markets and stationary power markets worldwide. The Company sells and develops a range of fuel cell products and services including hydrogen fuel cell low-temperature proton exchange membrane (PEM) systems for motive and stationary power and a high-temperature fuel cell system for residential and light commercial co-generation.

Chelsea Therapeutics (NASDAQ:CHTP) has reported the results and plans to modify Study 306 to focus on reduction in falls associated with neurogenic orthostatic hypotension. Company announces plans to modify Study 306, a Phase III study of NORTHERA in symptomatic neurogenic orthostatic hypotension associated with Parkinson's disease following a futility determination at the planned interim analysis of the study's primary endpoint. Secondary showed dramatic reduction in falls and clear signs of therapeutic activity associated with Northera in the first 51 patients to complete Study 306.

However with that said, stock took an opposite turn as investors jumped out in panic as the news was perceived pessimistic if they had to modify the study 306. Shares lost 0.54% to settle at $5.02 with a 558,908 shares volume. That significant drop is overdone, there might be an opportunity lingering to make a quick 2-3% in the interim.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

BPZ Energy (NYSE:BPZ) announced its $50 million 2011 capital expenditures plan for continued development of the Company's assets in northwest Peru. The majority of the capital budget is expected to be spent on offshore Block Z1, primarily for design and construction of an additional production platform for the Corvina oil field; as well as, for injection equipment to be installed on the platform in the Albacora oil field by year-end 2011.

Shares have gained moderately 0.66% to settle at $6.14 with a volume of 1,868,922 shares traded.

BPZ Resources, Inc. is an independent oil and gas company focused on the exploration, development and production of oil and natural gas in Peru and Ecuador. The Company has the exclusive rights and license agreements for oil and gas exploration and production covering approximately 2.2 million acres in four blocks in northwest Peru and off the northwest coast of Peru in the Gulf of Guayaquil. BPZ also owns a 10% non-operated working interest in an oil and gas producing property, Block 2, located in the southwest region of Ecuador.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has not been compensated for any stocks listed in this stock news report

As the market is making new highs, some analysts predict that the S&P 500 is due for a pullback at 1200 range. Whether this is true or not the market seems to be in an uptrend with Dow Jones rising above 12,100 and NASDAQ reaching 2800. The fact that some companies are even increasing their dividends and the inflow of mergers and acquisitions by midsized companies goes to show that the recovery is starting to pick up speed.

Following are some of the stocks that are making headlines today that are considered microcap, so without further ado let's dive right in. Ampal American (NASDAQ: AMPL) recently announced that it has been advised by the East Mediterranean gas, in which the company has a 12.6% interest, was not damaged by the recent explosion of a gas metering station in Egypt. Because of this the supply gas to EMG, and therefore to EMG's immediate Israeli clients has been interrupted by a fire in a facility not related to EMG. Reuters stated that the gas supply to the EMG should resume operations within a week.

To our surprise the stock has been rallying 5.45% at Monday's open with a 21,085 shares volume which is fairly moderate compared to the three month average volume of 27,223. The stock has been trading in the last 52 weeks between $1.39 up to three dollars even. I would definitely keep an eye out on this stock especially within the next week to see if there is gas supply operations resume within the given time table.

Ampal-American Israel Corporation (Ampal) primarily acquires interests in businesses located in the State of Israel or that are Israel-related. The Company's investment focus is principally on companies or ventures where Ampal can exercise significant influence, on its own or with investment partners, and can use its management experience to enhance those investments. It focuses to invest in undervalued assets with an emphasis in sectors, such as: Energy, Chemicals, Telecommunications, Real Estate, Project Development and Leisure Time.

Our next company is Crystallex (AMEX:KRY) that recently it received a letter from the corporation Venezolana de Guayana then stated that the company's mine operating contract for the loss of Christina's project in Bolivar state Venezuela, has been unilaterally terminated by the CVG. The letter also enclosed a copy of a resolution passed by the CVG on February 3, 2011 which also stated that the MOC is unilaterally terminated.

Investors and traders of course have viewed this news as a pessimistic outcome as the shares of the stock KRY has tumbled 37% at the market open with an astounding volume of 10.6 million shares. The stock has already been in a downtrend for the past seven months as a 52-week range and zigzag around $.13 up to $.77

Crystallex international Corporation normally engages in the development of gold properties in Venezuela. It has principally owned interest in the last Christina's gold project that is located in Sifontes Municipality in Bolivar State Venezuela. the company was founded back in 1984 and is headquartered in Toronto Canada.

EpiCept (NASDAQ: EPCT) has been under a tremendous pressure to keep it stuck price per share above one dollar in the last few months. it today announced positive results coming from the phase 2B trial evaluating the efficacy and safety of the attic NP1chemo that chemo therapy induced peripheral neuropathy. The results of the trial with the intent to treat population demonstrated that the change in average daily new Europe passing intensity scores in the and P1 group has achieved a statistically significant reduction in CPN intensity versus placebo which was the trial's primary endpoint in addition the prespecified subgroup of the ITT population those patients who previously received tax saying chemotherapy also have shown a statistically significant reduction in average daily Europe passing intensity scores this subgroup constitute more than 50% of the ITT population.

Because of this stocks have rallied almost 16% of the market open with a volume of three times the average at 666,000 hundred and 24 shares traded so far. Another $.13 and the company can meet NASDAQ's minimum requirements to sustain its listing on the exchange. For the past two weeks the company has traded between $.33 and $2.45 a share.

EpiCept Corp. normally focuses on the development and commercialization of pharmaceutical products for the treatment of cancer and pain in the United States and Germany one of its main products that has had quite a success is the Ceplene, which was used for the treatment of acute myeloid leukemia.

Another company that is in play today is Inovio Pharmaceuticals (AMEX: INO). the company has gone up 1.55% of the market opens with a volume of 243,887 shares traded by midday. It recently announced that its new generation DNA vaccine delivery technology, which provides the powerful enabling capabilities of LA troll proration without contacting the skin. implementing this new technology can also provide other desirable benefits. By eliminating the insertion of needles used in the conventional electroporation process and reducing the electrical pulsing 2 ns makes this contact contactless device even more tolerable than current electroporation devices.

This companyhas a market capitalization of $135.5 million and has been trading between $.76 and $1.56 in the past 52-week range and has a target of one year estimate of $2.96. The company does not pay dividends at this time.

The company is engaged in the discovery development and delivery of DNA vaccines with a focus on cancers and other infectious diseases. It's the Syncon technology enables the design of DNA-based vaccines are capable of providing cross protection against unmatched strains of pathogens such as influenza.

Almaden Minerals (AMEX: AAU) today announced that to drill explorations and definition programs are now underway at the company's wholly owned Ixtaca gold and silver project located in Puebla state, Mexico. The company's goals for the year 2011 at Almaden is to outline the potential of the Ixtaca zone by a minimum CAD to million drill program. In addition the company states that the drilling in 2011 is designed to explore the size potential of the Ixtaca Zone.

Almaden Minerals Limited, is considered to be an exploration stage company that engages in the acquisition exploration and development of mineral properties in Canada as well as the United States and Mexico. It holds interests in the elk gold and silver property compromising the Siwash gold deposits in Canada and the Caballo Blanco gold in Mexico.

BullsEyeMicrocaps.com is not a registered investment advisers or broker/dealer. BullsEyeMicrocaps.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: BullsEyeMicrocaps.com has not been compensated for any stocks listed in this stock news report.

Inovio Pharma (AMEX:INO) has recently announced the publication of the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon vaccine for prostate cancer targeting two antigens. The resultant data showed the induction of strong PSMA-specific cellular immune responses and also significant antigen specific seroconversion, illustrating that both humoral and cellular immune responses can be generated by this approach.

Stock recently rallied by 5.43% to settle at $1.36 with an increased volume of 896,104. Keep an eye on this one as the increase in volume might push the stock for another breakout.

The development of this new treatment for prostate cancer would be a significant medical advance given that present treatment options (surgery, radiation and hormone deprivation), while somewhat effective, all carry deleterious side effects and often do not confer long-term cure.

Inovio Pharmaceuticals, Inc. a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the publication of a scientific paper in the journal Human Vaccines detailing potent immune responses in a preclinical study of Inovio's SynCon(TM) DNA vaccine for prostate cancer targeting two antigens.

NovaBay Pharma (AMEX:NBY) has recently provided a synopsis of its accomplishment as well as the progress from 2010 and its outlook into 2011. NovaBay is in the process of developing commercial opportunities for its Aganocide portfolio of anti-infectives in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections.

Each of these market segments contain indications that are poorly served or have no approved FDA treatments available, with billion-dollar revenue potential. Company's strategy is to address these market opportunities either through partnerships and collaborations or by building an internal organization to strategically market its own products when appropriate from a commercial standpoint.

Shares have droped 0.58% to settle at $1.74 with a moderate volume of 53,654 shares traded by the opening bell.

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage pharmaceutical company, which is engaged in the discovery and development of synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments.

Plug Power (NASDAQ:PLUG) announced today that the NASDAQ Listing Qualifications Panel has granted the Company's request for continued listing on The NASDAQ Capital Market pursuant to an extension of time to comply with the minimum $1.00 bid price requirement. In accordance with the Panel's decision, before June 6, 2011, the Company must evidence compliance with the bid price requirement for a minimum of ten consecutive business days.

Shares have skyrocketed 11.46% to settle at $0.834 with an increased volume of 1,675,158 shares traded so far.

Plug Power Inc. is a development-stage company engaged in the design, development and manufacture of fuel cell systems for industrial off-road (forklift or material handling) markets and stationary power markets worldwide. The Company sells and develops a range of fuel cell products and services including hydrogen fuel cell low-temperature proton exchange membrane (PEM) systems for motive and stationary power and a high-temperature fuel cell system for residential and light commercial co-generation.

Chelsea Therapeutics (NASDAQ:CHTP) has reported the results and plans to modify Study 306 to focus on reduction in falls associated with neurogenic orthostatic hypotension. Company announces plans to modify Study 306, a Phase III study of NORTHERA in symptomatic neurogenic orthostatic hypotension associated with Parkinson's disease following a futility determination at the planned interim analysis of the study's primary endpoint. Secondary showed dramatic reduction in falls and clear signs of therapeutic activity associated with Northera in the first 51 patients to complete Study 306.

However with that said, stock took an opposite turn as investors jumped out in panic as the news was perceived pessimistic if they had to modify the study 306. Shares plunged 18.77% to settle at $5.02 with a 3,284,908 shares volume. That significant drop is overdone, there might be an opportunity lingering to make a quick 2-3% in the interim.

Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases.

BPZ Energy (NYSE:BPZ) announced its $50 million 2011 capital expenditures plan for continued development of the Company's assets in northwest Peru. The majority of the capital budget is expected to be spent on offshore Block Z1, primarily for design and construction of an additional production platform for the Corvina oil field; as well as, for injection equipment to be installed on the platform in the Albacora oil field by year-end 2011.

Shares have gained moderately 0.66% to settle at $6.14 with a volume of 1,868,922 shares traded.

BPZ Resources, Inc. is an independent oil and gas company focused on the exploration, development and production of oil and natural gas in Peru and Ecuador. The Company has the exclusive rights and license agreements for oil and gas exploration and production covering approximately 2.2 million acres in four blocks in northwest Peru and off the northwest coast of Peru in the Gulf of Guayaquil. BPZ also owns a 10% non-operated working interest in an oil and gas producing property, Block 2, located in the southwest region of Ecuador.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk. Always do you own homework before investing in any stock.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has not been compensated for any stocks listed in this stock news report